Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex.

Jaiprasart P, Yeung BZ, Lu Z, Wientjes MG, Cui M, Hsieh CM, Woo S, Au JL.

J Control Release. 2018 Jan 28;270:101-113. doi: 10.1016/j.jconrel.2017.12.001. Epub 2017 Dec 22.

PMID:
29203416
2.

Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.

Wang J, Yeung BZ, Cui M, Peer CJ, Lu Z, Figg WD, Guillaume Wientjes M, Woo S, Au JL.

J Control Release. 2017 Dec 28;268:147-158. doi: 10.1016/j.jconrel.2017.10.020. Epub 2017 Oct 18.

PMID:
29054369
3.

Rehabilitation Needs of the Elderly Patient with Cancer.

Padro-Guzman J, Moody JP, Au JL.

Phys Med Rehabil Clin N Am. 2017 Nov;28(4):811-819. doi: 10.1016/j.pmr.2017.06.012. Review.

PMID:
29031345
4.

Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.

Zhao L, Au JL, Wientjes MG.

Curr Cancer Drug Targets. 2017;17(8):735-755. doi: 10.2174/1568009617666170330154054.

5.

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke.

Au JL, Weishaupt N, Nell HJ, Whitehead SN, Cechetto DF.

J Vis Exp. 2016 Mar 22;(109). doi: 10.3791/53089.

6.

Targeted Antioxidant, Catalase-SKL, Reduces Beta-Amyloid Toxicity in the Rat Brain.

Nell HJ, Au JL, Giordano CR, Terlecky SR, Walton PA, Whitehead SN, Cechetto DF.

Brain Pathol. 2017 Jan;27(1):86-94. doi: 10.1111/bpa.12368. Epub 2016 Jun 13.

PMID:
26919450
7.

Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Au JL, Yeung BZ, Wientjes MG, Lu Z, Wientjes MG.

Adv Drug Deliv Rev. 2016 Feb 1;97:280-301. doi: 10.1016/j.addr.2015.12.002. Epub 2015 Dec 11. Review.

8.

High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA.

Yeung BZ, Lu Z, Wientjes GM, Au JL.

AAPS J. 2015 Nov;17(6):1475-82. doi: 10.1208/s12248-015-9812-y. Epub 2015 Aug 19.

9.

Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.

Wang J, Lu Z, Wang J, Cui M, Yeung BZ, Cole DJ, Wientjes MG, Au JL.

J Control Release. 2015 Oct 28;216:103-10. doi: 10.1016/j.jconrel.2015.08.012. Epub 2015 Aug 10.

10.

Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.

Au JL, Lu Z, Wientjes MG.

AAPS J. 2015 Sep;17(5):1065-79. doi: 10.1208/s12248-015-9785-x. Epub 2015 Jun 19. Review.

11.

Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.

Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z.

J Urol. 2015 Jul;194(1):230-7. doi: 10.1016/j.juro.2015.02.036. Epub 2015 Feb 11.

12.

Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin.

Gan Y, Lu J, Yeung BZ, Cottage CT, Wientjes MG, Au JL.

AAPS J. 2015 Jan;17(1):268-76. doi: 10.1208/s12248-014-9703-7. Epub 2014 Nov 26.

13.

Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids.

Wientjes MG, Yeung BZ, Lu Z, Wientjes MG, Au JL.

J Control Release. 2014 Oct 28;192:10-8. doi: 10.1016/j.jconrel.2014.06.050. Epub 2014 Jul 2.

14.

Multiscale tumor spatiokinetic model for intraperitoneal therapy.

Au JL, Guo P, Gao Y, Lu Z, Wientjes MG, Tsai M, Wientjes MG.

AAPS J. 2014 May;16(3):424-39. doi: 10.1208/s12248-014-9574-y. Epub 2014 Feb 26.

15.

Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

Wang J, Lu Z, Yeung BZ, Wientjes MG, Cole DJ, Au JL.

J Control Release. 2014 Mar 28;178:79-85. doi: 10.1016/j.jconrel.2014.01.012. Epub 2014 Jan 23.

16.

Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma.

Alvarez FJ, Kisseberth W, Hosoya K, Lara-Garcia A, Kosarek C, Murahari S, Au JL, Wientjes MG, Couto J, Couto G.

J Am Anim Hosp Assoc. 2014 Jan-Feb;50(1):12-8. doi: 10.5326/JAAHA-MS-5958. Epub 2013 Nov 11.

PMID:
24216494
17.

Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors.

Lu Z, Tsai M, Wang J, Cole DJ, Wientjes MG, Au JL.

Curr Cancer Drug Targets. 2014;14(1):70-8.

PMID:
24200079
18.

Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.

Tsai M, Lu Z, Wientjes MG, Au JL.

J Control Release. 2013 Dec 28;172(3):737-44. doi: 10.1016/j.jconrel.2013.09.011. Epub 2013 Sep 20.

19.

Predictive models of diffusive nanoparticle transport in 3-dimensional tumor cell spheroids.

Gao Y, Li M, Chen B, Shen Z, Guo P, Wientjes MG, Au JL.

AAPS J. 2013 Jul;15(3):816-31. doi: 10.1208/s12248-013-9478-2. Epub 2013 Apr 20.

20.

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, Sanderson RD.

FEBS J. 2013 May;280(10):2294-306. doi: 10.1111/febs.12168. Epub 2013 Mar 4. Review.

21.

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):49-56. doi: 10.1007/s00280-012-1887-x. Epub 2012 May 22.

22.

Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Wang J, Lu Z, Gao Y, Wientjes MG, Au JL.

Nanomedicine (Lond). 2011 Nov;6(9):1605-20. doi: 10.2217/nnm.11.141. Review.

23.

Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability.

Li Y, Wang J, Gao Y, Zhu J, Wientjes MG, Au JL.

AAPS J. 2011 Dec;13(4):585-97. doi: 10.1208/s12248-011-9298-1. Epub 2011 Sep 10.

24.

Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Li Y, Wang J, Wientjes MG, Au JL.

Adv Drug Deliv Rev. 2012 Jan;64(1):29-39. doi: 10.1016/j.addr.2011.04.006. Epub 2011 May 3. Review.

25.

Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.

Wong HL, Shen Z, Lu Z, Wientjes MG, Au JL.

Mol Pharm. 2011 Jun 6;8(3):833-40. doi: 10.1021/mp1004383. Epub 2011 Mar 29.

26.

Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.

Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL.

J Urol. 2011 Apr;185(4):1478-83. doi: 10.1016/j.juro.2010.11.091. Epub 2011 Feb 19.

27.

Regional measurements of surface deviation volume in worn polyethylene joint replacement components.

Teeter MG, Milner JS, Au JL, Lorusso D, Naudie DD, Holdsworth DW.

J Long Term Eff Med Implants. 2010;20(1):49-56.

PMID:
21284588
28.

Combination intravesical hyperthermia and chemotherapy for bladder cancer.

Au JL, Wientjes MG.

Oncology (Williston Park). 2010 Nov 15;24(12):1155, 1160. No abstract available.

29.

Intraperitoneal therapy for peritoneal cancer.

Lu Z, Wang J, Wientjes MG, Au JL.

Future Oncol. 2010 Oct;6(10):1625-41. doi: 10.2217/fon.10.100. Review.

30.

Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.

Hu L, Wientjes MG, Li J, Au JL.

AAPS J. 2010 Dec;12(4):586-91. doi: 10.1208/s12248-010-9219-8. Epub 2010 Jul 13.

31.

Delivery of siRNA therapeutics: barriers and carriers.

Wang J, Lu Z, Wientjes MG, Au JL.

AAPS J. 2010 Dec;12(4):492-503. doi: 10.1208/s12248-010-9210-4. Epub 2010 Jun 11. Review.

32.

Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Li J, Wientjes MG, Au JL.

AAPS J. 2010 Jun;12(2):223-32. doi: 10.1208/s12248-010-9181-5. Epub 2010 Mar 3. Review.

33.

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.

Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1019-29. doi: 10.1007/s00280-010-1252-x. Epub 2010 Jan 28.

34.

Comparison of methods for evaluating drug-drug interaction.

Zhao L, Au JL, Wientjes MG.

Front Biosci (Elite Ed). 2010 Jan 1;2:241-9.

35.

MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer.

Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y.

Cancer Cell. 2009 Jan 6;15(1):9-20. doi: 10.1016/j.ccr.2008.11.013.

36.

Risk-adapted use of intravesical chemotherapy.

Lerner SP, Au JL.

BJU Int. 2008 Nov;102(9 Pt B):1247-53. doi: 10.1111/j.1464-410X.2008.07967.x. No abstract available.

PMID:
19035889
37.

Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.

Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL.

J Pharmacol Exp Ther. 2008 Dec;327(3):673-82. doi: 10.1124/jpet.108.140095. Epub 2008 Sep 9.

38.

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.

Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL.

Ann Oncol. 2008 Nov;19(11):1903-9. doi: 10.1093/annonc/mdn412. Epub 2008 Jul 15.

39.

Intravesical treatments of bladder cancer: review.

Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL.

Pharm Res. 2008 Jul;25(7):1500-10. doi: 10.1007/s11095-008-9566-7. Epub 2008 Mar 28. Review.

40.

Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.

Walsh CT, Wei Y, Wientjes MG, Au JL.

J Transl Med. 2008 Jan 18;6:4. doi: 10.1186/1479-5876-6-4.

41.

Biodegradable intraprostatic doxorubicin implants.

Ortiz R, Au JL, Lu Z, Gan Y, Wientjes MG.

AAPS J. 2007 Jun 29;9(2):E241-50.

42.

Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.

Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL.

Pharm Res. 2007 Sep;24(9):1691-701. Epub 2007 Apr 20.

43.

Tumor priming enhances delivery and efficacy of nanomedicines.

Lu D, Wientjes MG, Lu Z, Au JL.

J Pharmacol Exp Ther. 2007 Jul;322(1):80-8. Epub 2007 Apr 9.

44.
45.

Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.

Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM, Au JL, Wientjes MG.

J Vet Intern Med. 2006 Sep-Oct;20(5):1172-7.

46.

Protection against chemotherapy-induced alopecia.

Wang J, Lu Z, Au JL.

Pharm Res. 2006 Nov;23(11):2505-14. Review.

PMID:
16972183
47.

Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors.

Gan Y, Wientjes MG, Au JL.

Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8.

PMID:
16741658
48.

Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

Chen D, Song SH, Wientjes MG, Yeh TK, Zhao L, Villalona-Calero M, Otterson GA, Jensen R, Grever M, Murgo AJ, Au JL.

Pharm Res. 2006 Jun;23(6):1265-74. Epub 2006 May 25.

PMID:
16715360
49.

Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.

Lu Z, Wientjes TS, Au JL.

Pharm Res. 2005 Jul;22(7):1069-78. Epub 2005 Jul 22.

PMID:
16028007
50.

Formulating paclitaxel in nanoparticles alters its disposition.

Yeh TK, Lu Z, Wientjes MG, Au JL.

Pharm Res. 2005 Jun;22(6):867-74. Epub 2005 Jun 8.

PMID:
15948030

Supplemental Content

Support Center